Matthew is an associate editor for The American Journal of Managed Care® (AJMC®). He joined AJMC® in 2019 and creates content for Medical World News®, a 24-hour online program developed MJH Life Sciences® focusing on pressing topics within managed care, as well as the nonwork-related activities of health care stakeholders.
He has a BA in journalism & media studies and economics from Rutgers University. You can connect with Matthew on LinkedIn.
Paul G. Alexander, MD, MPH, executive vice president and chief health equity and transformation officer, RWJBarnabas Health, spoke on population health management strategies employed by his organization to identify and address health disparities in the communities they serve.
Read More
Health Equity Decision-making: A Q&A With Dr N. Benjamin Fredrick
January 23rd 2023N. Benjamin Fredrick, MD, of Penn State Hershey Medical Center and Penn State University College of Medicine, speaks on the key themes he presented during his session at the 2023 Health Equity Summit in San Diego, California, as well as topics related to the measurement, creation, and implementation of health equity initiatives.
Read More
Wildfire Air Pollution Linked With Increased Rates of Psoriasis Clinic Visits Among Adults
January 22nd 2023After a delayed lag period, air pollution from a wildfire was associated with modestly increased rates of clinic visits for psoriasis among adults starting 5 weeks after the fire and peaking at 8 to 9 weeks after the fire.
Read More
Dr Kirsten Johansen on Benefits of Oral Therapies for the Management of CKD
January 22nd 2023Kirsten Johansen, MD, director of nephrology, Hennepin Healthcare, speaks on the impact that an oral medication would have on the management of chronic kidney disease (CKD) for patients both on and not on dialysis.
Read More
No difference in treatment efficacy was observed between intranasal mometasone furoate and saline for the management of sleep-disordered breathing (SDB) symptoms in children, with findings indicating that almost one-half of children with SDB could be initially managed in the primary care setting.
Read More
Examining Patient Preferences for Biologic Use in Psoriasis
January 13th 2023Following COVID-19–related lockdown measures, preferences for the use of biologics among Japanese patients with psoriasis addressed administration route, visits, and risk of serious infections requiring hospitalization, with some differences observed between specific subgroups.
Read More
Newer Drugs for Epilepsy Less Likely to Be Prescribed to Black, Latino Patients on Medicaid
January 11th 2023Patients with epilepsy on Medicaid insurance of Black, Latino, and Native Hawaiian and Other Pacific Island ethnicity were associated with lower odds of being on newer, second- and third-generation, antiseizure medications compared with White individuals.
Read More
Spotlighting Health Disparities for Black Americans With Multiple Myeloma and Potential Solutions
January 11th 2023Black Americans with multiple myeloma face disparities in incidence of disease, survival outcomes, and use of evidence-based treatment, which may be exacerbated by socioeconomic factors.
Read More
Disparities in Multiple Myeloma Treatment, Mortality Risk Observed Among Hispanic Americans
January 9th 2023Despite greater incidence of multiple myeloma (MM) reported among Hispanic Americans, these populations report less MM maintenance therapy, longer time from MM diagnosis to novel therapy initiation, and higher in-hospital mortality rates.
Read More
Developing a Framework to Address Health Inequities in Epilepsy
January 6th 2023A review explored the connection between 4 domains (structural, sociocultural, health care, and physiological) contributing to the persistence of inequities in epilepsy risk and outcomes in the United States, as well as key areas of intervention to promote health equity.
Read More
Improved Work-, Study-Related Productivity Shown With Tildrakizumab in Patients With Psoriasis
January 5th 2023Abstract findings presented at the 2022 American Academy of Dermatology Annual Meeting showed that patients with moderate to severe psoriasis achieved improvement in work-/study-related productivity with tildakizumab vs placebo after only 2 doses.
Read More
Examining Modifiable Risk Factors in Psoriasis
January 5th 2023Findings of a Mendelian randomization analysis showed that greater body mass index as a child and adult and incidence of smoking were associated with an increased risk of psoriasis, whereas having more education was cited as a potential protective factor against development.
Read More
Michael Thompson on Steps Needed to Bolster Health Equity Initiatives in the Workplace
January 4th 2023Michael Thompson, president and CEO of the National Alliance of Healthcare Purchaser Coalitions (National Alliance), addressed the current state of health equity strategies in the workplace and how employers can better address inequities in their benefit designs, programs, and policies in the near future.
Read More
Top 5 Most-Read Dermatology Content of 2022
December 30th 2022This year’s most-read articles on dermatology covered the first and only FDA-approved treatment for repigmentation in patients with vitiligo, as well as other therapies for the treatment of acne, hidradenitis suppurativa, and more.
Read More
Top 5 Most-Read Atopic Dermatitis Articles of 2022
December 27th 2022This year’s most-read articles on atopic dermatitis (AD) examined AD as a risk factor for other neurological and attention-deficit conditions and efforts to improve the detection of other comorbid conditions associated with the common skin condition.
Read More
Adjuvant Baricitinib, Topical Corticosteroids Show Long-term Efficacy in Moderate-to-Severe AD
December 22nd 2022Adult patients with moderate-to-severe atopic dermatitis (AD) in the phase 3 BREEZE-AD7 study showed sustained improvement of AD signs and symptoms after 68 weeks with combination treatment of bariticitinib and topical corticosteroids.
Read More
Dr Jessica Allegretti Explains Rebyota’s Mechanism of Action for the Prevention of Recurrent CDI
December 21st 2022Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, explained the mechanism of action for Rebyota, the first fecal transplant therapy approved by the FDA for the prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Read More
Top 5 Most-Viewed Content in Leukemia and Lymphoma for 2022
December 20th 2022The top 5 most-read content in leukemia and lymphoma for 2022 addressed chimeric antigen receptor T-cell therapy, updates in recommended treatment, and President Joe Biden’s announcement on the return of the Cancer Moonshot.
Read More